Apple pushes into clinical trials with new FDA nod for Apple Watch

The Apple Watch has recently been recognized by the Food and Drug Administration (FDA) with a qualification that positions the smartwatch as a valuable resource for medical device companies demonstrating the effectiveness of prevalent heart treatments.

Just last week, the Apple Watch's Atrial Fibrillation History feature was officially qualified under the FDA's Medical Device Development Tools (MDDT) program. Introduced in 2022, this feature provides estimates of a user's A-fib burden—the amount of time their heart remains in atrial fibrillation. Atrial fibrillation is a condition characterized by an irregular heartbeat that can lead to symptoms like shortness of breath and fatigue, and it increases the risk of stroke.

This FDA qualification indicates that the feature can now be used as a secondary endpoint in clinical trials, eliminating the need for additional validation. Specifically, the Apple Watch is approved to serve as a secondary endpoint in studies evaluating cardiac ablation devices. These devices aim to alleviate A-fib by using extreme heat or cold to create scars in the heart tissue that disrupt faulty electrical signals. The latest advancement in this technology, pulsed field ablation, utilizes controlled electric fields to create these scars, offering a safer alternative to traditional thermal energy methods.

‍

Read more

‍